Commercial production to commence in the third quarter of FY24

Aurobindo Pharma’s generic FDC drug to treat children living with HIV gets U.S. FDA’s tentative nod

FDC’s June quarter profit rose 55% YoY to Rs 109.81 crore, and its board approved buyback of shares worth Rs 155 crore.

FDC Stock Hits Record High After Q1 Profit Jumps, Board Approves Share Buyback

The government banned 14 FDCs in June that affected around Rs 824 crore of the domestic pharmaceuticals market

FDC Ban Latest News: Govt planning more crackdowns on vitamin and mineral combination drugs

The BSE Healthcare index has reversed its downtrend and is on track for a potential rally. Positive chart indicators and strong support levels suggest a bullish outlook. Consider long-term opportunities in healthcare stocks like Aurobindo Pharma, Zydus Lifesciences, Natco Pharma, FDC, and Jubilant P…

Chart Focus: BSE Healthcare Index Shows Bullish Reversal, Points to Potential Rally

The government had announced a ban on 14 FDC drugs on June 2 this year on the recommendations of an expert committee, saying there was ”no therapeutic justification” for these medicines

Delhi HC Seeks Centre’s Stand on Challenge to Ban on Fixed Dose Combination Drugs - News18

Sectorally, buying was seen in realty, IT, telecom, oil & gas, and energy stocks, while some selling was seen in capital goods and power stocks. ​Stocks in focus included names like FDC, which hit a fresh 52-week high, Suzlon, which rallied over 9% and Go Fashion, which fell nearly 5% on Monday.

Breakout Stocks: How are FDC, Suzlon Energy and Go Fashion looking on charts for Tuesday

The Centre’s ban on 14 fixed-dose-combination (FDC) drugs is being accepted across pharmaceutical and civil society lines, as it comes after a long drawn battle to clear the market off “irrational and unscientific” medicines

‘Ban on 14 FDC drugs unlikely to impact consumers’

The Indian government has banned 14 types of fixed-dose combination (FDC) medicines due to a lack of therapeutic justification and potential risks to humans, according to an expert panel’s recommendations. FDCs mix two or more active ingredients in a fixed ratio. The FDCs that have been banned inclu…

India bans 14 fixed-dose medicines for likely posing risks to health

Fourteen fixed-dose combinations (FDC) medicines found to lack therapeutic relevance have been banned by the Central Government through a gazette notification issued over the weekend.

Govt. bans 14 combination drugs used to treat common ailments

FDC Standalone March 2023 Net Sales at Rs 431.20 crore, up 28.1% Y-o-Y

In case of Fixed dose combinations (FDC) where one component is going off patent the ceiling price will be revised by reducing the present ceiling price by 50%, it further said. According to the notification, “the retail price of the new drug shall be arrived at by reducing fifty percent,” it said. …

Prices of drugs going off patent to be slashed to 50%

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

FDC Limited is a pharmaceutical company  engaged in manufacture of specialized formulations, and oral rehydration salts (ORS). Its brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.

F D C Ltd